{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T01:22:51Z","timestamp":1794360171242,"version":"4.9.0"},"reference-count":90,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background\/Aims<\/jats:title>\n                  <jats:p>Inflammatory bowel disease (IBD) is associated with increased cardiovascular (CV) risk. Advanced therapies that treat IBD may modify this risk. Our systematic review and meta-analysis aim to investigate the association between IBD, its subtypes (Crohn\u2019s disease and ulcerative colitis), and its therapies, with CV disease.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Medline, Embase, Scopus, and Web of Science were searched from January 2000 to November 2023. Studies examining the relationship between IBD and the CV outcomes of incident myocardial infarction (MI), ischemic heart disease (IHD), cerebrovascular accident (CVA), and major adverse cardiovascular events (MACE) were included. Pooled hazard ratios (HRs) were calculated using inverse-variance weighted random effects meta-analysis. Incidence rate differences for MACE were derived from studies comparing IBD therapies.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Fourteen studies evaluating CV outcomes were included. Of the 2\u2005232\u2005375 individuals, 10.8% were IBD patients, mean age was 47.3 years, and 48.4% were male. Inflammatory bowel disease was significantly associated with MI (HR 1.29, 95% CI, 1.07-1.56, I2\u2005=\u20050.87), IHD (HR 1.16, 95% CI, 1.01-1.33, I2\u2005=\u20050.60), CVA (HR 1.15, 95% CI, 1.09-1.20, I2\u2005=\u20050.30), and MACE (HR 1.19, 95% CI, 1.09-1.30, I2\u2005=\u20050.81). Incidence rate differences (events per 1000 patient-years) for MACE, calculated for 16 comparative studies, ranged from 90.3 fewer events in tofacitinib compared with placebo to an excess of 17.9 events in a vedolizumab group compared with anti-TNF\u03b1 biologics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There is an increased risk of MI, IHD, CVA, and MACE in IBD patients. Management of IBD needs to consider these risks and how it may be adjusted when selecting advanced therapies.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjaf078","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T09:32:12Z","timestamp":1746178332000},"source":"Crossref","is-referenced-by-count":20,"title":["Association between inflammatory bowel disease, current therapies, and cardiovascular events: a review and meta-analysis of data from 2.2 million individuals"],"prefix":"10.1093","volume":"19","author":[{"given":"David-Raj","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital , Perth ,","place":["Australia"]},{"name":"Medical School, The University of Western , Australia, Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2244-6033","authenticated-orcid":false,"given":"Gavin","family":"Huangfu","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital , Perth ,","place":["Australia"]},{"name":"Medical School, The University of Western , Australia, Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Yeaman","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Fiona Stanley Hospital , Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Sukudom","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital , Perth ,","place":["Australia"]},{"name":"Medical School, The University of Western , Australia, Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7222-7314","authenticated-orcid":false,"given":"Nick S R","family":"Lan","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital , Perth ,","place":["Australia"]},{"name":"Medical School, The University of Western , Australia, Perth ,","place":["Australia"]},{"name":"Harry Perkins Institute of Medical Research , Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0717-740X","authenticated-orcid":false,"given":"Girish","family":"Dwivedi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fiona Stanley Hospital , Perth ,","place":["Australia"]},{"name":"Medical School, The University of Western , Australia, Perth ,","place":["Australia"]},{"name":"Harry Perkins Institute of Medical Research , Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2816-3533","authenticated-orcid":false,"given":"Lena","family":"Thin","sequence":"additional","affiliation":[{"name":"Medical School, The University of Western , Australia, Perth ,","place":["Australia"]},{"name":"Department of Gastroenterology, Fiona Stanley Hospital , Perth ,","place":["Australia"]},{"name":"Harry Perkins Institute of Medical Research , Perth ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,7]]},"reference":[{"key":"2025071703213438500_CIT0001","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1056\/NEJMra2002697","article-title":"Pathophysiology of inflammatory bowel diseases","volume":"383","author":"Chang","year":"2020","journal-title":"N Engl J Med."},{"key":"2025071703213438500_CIT0002","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.hlc.2020.12.002","article-title":"Extrinsic and intrinsic responses in the development and progression of atherosclerosis","volume":"30","author":"Kuk","year":"2021","journal-title":"Heart Lung Circ."},{"key":"2025071703213438500_CIT0003","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","article-title":"Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions","volume":"276","author":"Raggi","year":"2018","journal-title":"Atherosclerosis."},{"key":"2025071703213438500_CIT0004","doi-asserted-by":"crossref","first-page":"e000062","DOI":"10.1161\/JAHA.113.000062","article-title":"Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies","volume":"2","author":"Armstrong","year":"2013","journal-title":"J Am Heart Assoc."},{"key":"2025071703213438500_CIT0005","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","article-title":"Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies","volume":"71","author":"Avina-Zubieta","year":"2012","journal-title":"Ann Rheum Dis."},{"key":"2025071703213438500_CIT0006","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1177\/2047487314546826","article-title":"Predictors of cardiovascular events in patients with systemic lupus erythematosus (SLE): a systematic review and meta-analysis","volume":"22","author":"Ballocca","year":"2015","journal-title":"Eur J Prev Cardiol."},{"key":"2025071703213438500_CIT0007","doi-asserted-by":"crossref","first-page":"e14280","DOI":"10.1111\/eci.14280","article-title":"Inflammation unites diverse acute and chronic diseases","volume":"54","author":"Libby","year":"2024","journal-title":"Eur J Clin Invest."},{"key":"2025071703213438500_CIT0008","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1007\/s12350-023-03204-8","article-title":"Anti-inflammatory effect of biologic therapy in patients with psoriatic disease: a prospective cohort FDG PET study","volume":"30","author":"Boczar","year":"2023","journal-title":"J Nucl Cardiol."},{"key":"2025071703213438500_CIT0009","doi-asserted-by":"crossref","first-page":"3057","DOI":"10.1007\/s12350-021-02830-4","article-title":"Anti-inflammatory effect of rosuvastatin in patients with HIV infection: an FDG-PET pilot study","volume":"29","author":"Boczar","year":"2022","journal-title":"J Nucl Cardiol."},{"key":"2025071703213438500_CIT0010","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cgh.2011.06.032","article-title":"No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn\u2019s disease","volume":"9","author":"Osterman","year":"2011","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0011","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.114.009990","article-title":"Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study","volume":"130","author":"Dregan","year":"2014","journal-title":"Circulation."},{"key":"2025071703213438500_CIT0012","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.cgh.2013.08.023","article-title":"Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0013","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1093\/ecco-jcc\/jjab058","article-title":"Vedolizumab and anti-tumour necrosis factor \u03b1 real-world outcomes in biologic-na\u00efve inflammatory bowel disease patients: results from the evolve study","volume":"15","author":"Bressler","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0014","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1053\/j.gastro.2020.02.030","article-title":"Efficacy of upadacitinib in a randomized trial of patients with active ulcerative colitis","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"2025071703213438500_CIT0015","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1056\/NEJMoa2109927","article-title":"Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis","volume":"386","author":"Ytterberg","year":"2022","journal-title":"N Engl J Med."},{"key":"2025071703213438500_CIT0016","doi-asserted-by":"crossref","DOI":"10.46658\/JBIMES-24-06","article-title":"Systematic reviews of etiology and risk","volume-title":"JBI Manual for Evidence Synthesis","author":"Moola","year":"2024"},{"key":"2025071703213438500_CIT0017","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials."},{"key":"2025071703213438500_CIT0018","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1037\/1082-989X.11.2.193","article-title":"Assessing heterogeneity in meta-analysis: Q statistic or I\u00b2 index","volume":"11","author":"Huedo-Medina","year":"2006","journal-title":"Psychol Methods."},{"key":"2025071703213438500_CIT0019","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ajg.2011.63","article-title":"Inflammatory bowel disease is associated with an increased incidence of cardiovascular events","volume":"106","author":"Yarur","year":"2011","journal-title":"Am J Gastroenterol."},{"key":"2025071703213438500_CIT0020","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.cgh.2022.08.035","article-title":"Inflammatory bowel disease is associated with an increased risk of incident acute arterial events: analysis of the United Kingdom biobank","volume":"21","author":"Alayo","year":"2023","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0021","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/MCA.0000000000000899","article-title":"Major acute cardiovascular events in patients with inflammatory bowel disease","volume":"32","author":"Gill","year":"2021","journal-title":"Coron Artery Dis."},{"key":"2025071703213438500_CIT0022","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2017-311279","article-title":"Association between chronic immune-mediated inflammatory diseases and cardiovascular risk","volume":"104","author":"Baena-D\u00edez","year":"2018","journal-title":"Heart."},{"key":"2025071703213438500_CIT0023","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1136\/gutjnl-2016-312735","article-title":"Tofacitinib for induction and maintenance therapy of Crohn\u2019s disease: results of two phase IIb randomised placebo-controlled trials","volume":"66","author":"Pan\u00e9s","year":"2017","journal-title":"Gut."},{"key":"2025071703213438500_CIT0024","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1056\/NEJMoa1112168","article-title":"Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"2025071703213438500_CIT0025","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1016\/j.cgh.2014.01.029","article-title":"A phase 2 study of tofacitinib, an oral Janus kinase inhibitor, in patients with Crohn\u2019s disease","volume":"12","author":"Sandborn","year":"2014","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0026","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1056\/NEJMoa1606910","article-title":"Tofacitinib as induction and maintenance therapy for ulcerative colitis","volume":"376","author":"Sandborn","year":"2017","journal-title":"N Engl J Med."},{"key":"2025071703213438500_CIT0027","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ecco-jcc\/jjad153","article-title":"Tofacitinib versus oral prednisolone for induction of remission in moderately active ulcerative colitis [orchid]: a prospective, open-label, randomized, pilot study","volume":"18","author":"Singh","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0028","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1093\/ecco-jcc\/jjac141","article-title":"Tofacitinib for the treatment of ulcerative colitis: an integrated summary of up to 7.8 years of safety data from the global clinical programme","volume":"17","author":"Sandborn","year":"2023","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0029","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/apt.15689","article-title":"Tofacitinib for ulcerative colitis: results of the prospective Dutch initiative on Crohn and colitis (ICC) registry","volume":"51","author":"Biemans","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2025071703213438500_CIT0030","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.14309\/ajg.0000000000002145","article-title":"Real-world evidence of tofacinitib in ulcerative colitis: short and long-term effectiveness and safety","volume":"118","author":"Chaparro","year":"2023","journal-title":"Am J Gastroenterol."},{"key":"2025071703213438500_CIT0031","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/ecco-jcc\/jjaa145","article-title":"Tofacitinib in ulcerative colitis: real-world evidence from the ENEIDA registry","volume":"15","author":"Chaparro","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0032","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1007\/s10620-022-07716-0","article-title":"Endo-histologic normalization is achievable with tofacitinib and is associated with improved clinical outcomes","volume":"68","author":"Cohen","year":"2023","journal-title":"Dig Dis Sci."},{"key":"2025071703213438500_CIT0033","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1093\/ibd\/izaa289","article-title":"Tofacitinib treatment safety in moderate to severe ulcerative colitis: comparison of observational population cohort data from the IBM marketscan\u00ae administrative claims database with tofacitinib trial data","volume":"27","author":"Curtis","year":"2021","journal-title":"Inflamm Bowel Dis."},{"key":"2025071703213438500_CIT0034","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/j.cgh.2020.06.050","article-title":"Safety of tofacitinib in a real-world cohort of patients with ulcerative colitis","volume":"19","author":"Deepak","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0035","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.cgh.2020.10.025","article-title":"Real-world effectiveness and safety of tofacitinib in Crohn\u2019s disease and IBD-U: a multicenter study from the tropic consortium","volume":"19","author":"Fenster","year":"2021","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0036","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1093\/ecco-jcc\/jjaa075","article-title":"Real-world effectiveness of tofacitinib for moderate to severe ulcerative colitis: a multicentre UK experience","volume":"14","author":"Honap","year":"2020","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0037","doi-asserted-by":"crossref","first-page":"5206","DOI":"10.1007\/s10620-022-07404-z","article-title":"Comparative risk of thrombotic and cardiovascular events with tofacitinib and anti-TNF agents in patients with inflammatory bowel diseases","volume":"67","author":"Kochar","year":"2022","journal-title":"Dig Dis Sci."},{"key":"2025071703213438500_CIT0038","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.dld.2019.10.003","article-title":"Real-world evidence of tofacitinib effectiveness and safety in patients with refractory ulcerative colitis","volume":"52","author":"Lair-Mehiri","year":"2020","journal-title":"Dig Liver Dis."},{"key":"2025071703213438500_CIT0039","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.3346\/jkms.2022.37.e123","article-title":"The comparative risk of serious adverse events with tofacitinib and TNF inhibitors in patients with ulcerative colitis: the Korean experience as revealed by a national database","volume":"37","author":"Seo","year":"2022","journal-title":"J Korean Med Sci."},{"key":"2025071703213438500_CIT0040","doi-asserted-by":"crossref","first-page":"17562848231154103","DOI":"10.1177\/17562848231154103","article-title":"Real-life effectiveness and safety of tofacitinib treatment in patients with ulcerative colitis: a KASID multicenter cohort study","volume":"16","author":"Shin","year":"2023","journal-title":"Ther Adv Gastroenterol."},{"key":"2025071703213438500_CIT0041","doi-asserted-by":"crossref","first-page":"115","DOI":"10.5217\/ir.2020.00030","article-title":"Rapid prediction of 1-year efficacy of tofacitinib for treating refractory ulcerative colitis","volume":"19","author":"Shimizu","year":"2021","journal-title":"Intest Res."},{"key":"2025071703213438500_CIT0042","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/apt.17248","article-title":"Effectiveness and safety of tofacitinib for ulcerative colitis: two-year results of the ICC registry","volume":"57","author":"Straatmijer","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"2025071703213438500_CIT0043","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1093\/ecco-jcc\/jjad158","article-title":"Mitigating the risk of tofacitinib-induced adverse events in the elderly population with ulcerative colitis","volume":"18","author":"Viola","year":"2024","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0044","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1007\/s10620-019-05492-y","article-title":"Real-world experience with tofacitinib in IBD at a tertiary center","volume":"64","author":"Weisshof","year":"2019","journal-title":"Dig Dis Sci."},{"key":"2025071703213438500_CIT0045","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/S0140-6736(16)32537-5","article-title":"Clinical remission in patients with moderate-to-severe Crohn\u2019s disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial","volume":"389","author":"Vermeire","year":"2017","journal-title":"Lancet (London, England)"},{"key":"2025071703213438500_CIT0046","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1053\/j.gastro.2020.01.047","article-title":"Efficacy and safety of upadacitinib in a randomized trial of patients with Crohn\u2019s disease","volume":"158","author":"Sandborn","year":"2020","journal-title":"Gastroenterology."},{"key":"2025071703213438500_CIT0047","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","article-title":"Filgotinib as induction and maintenance therapy for ulcerative colitis (selection): a phase 2b\/3 double-blind, randomised, placebo-controlled trial","volume":"397","author":"Feagan","year":"2021","journal-title":"Lancet (London, England)"},{"key":"2025071703213438500_CIT0048","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1016\/S0140-6736(22)00581-5","article-title":"Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials","volume":"399","author":"Danese","year":"2022","journal-title":"Lancet (London, England)"},{"key":"2025071703213438500_CIT0049","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1056\/NEJMoa2212728","article-title":"Upadacitinib induction and maintenance therapy for Crohn\u2019s disease","volume":"388","author":"Loftus","year":"2023","journal-title":"N Engl J Med."},{"key":"2025071703213438500_CIT0050","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn\u2019s disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med."},{"key":"2025071703213438500_CIT0051","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1093\/ecco-jcc\/jjac030","article-title":"Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension","volume":"16","author":"Abreu","year":"2022","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0052","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med."},{"key":"2025071703213438500_CIT0053","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/apt.15706","article-title":"The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn\u2019s disease refractory to anti-tumour necrosis factor","volume":"51","author":"Alric","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2025071703213438500_CIT0054","doi-asserted-by":"crossref","first-page":"e2234200","DOI":"10.1001\/jamanetworkopen.2022.34200","article-title":"Comparative outcomes and safety of vedolizumab vs tumor necrosis factor antagonists for older adults with inflammatory bowel diseases","volume":"5","author":"Singh","year":"2022","journal-title":"JAMA Network Open."},{"key":"2025071703213438500_CIT0055","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.cgh.2021.12.030","article-title":"Upadacitinib was efficacious and well-tolerated over 30 months in patients with Crohn\u2019s disease in the CELEST extension study","volume":"20","author":"D\u2019Haens","year":"2022","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0056","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ajg.2017.479","article-title":"Increased mortality rates with prolonged corticosteroid therapy when compared with antitumor necrosis factor-\u03b1-directed therapy for inflammatory bowel disease","volume":"113","author":"Lewis","year":"2018","journal-title":"Am J Gastroenterol."},{"key":"2025071703213438500_CIT0057","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study","volume":"69","author":"Kirchgesner","year":"2020","journal-title":"Gut."},{"key":"2025071703213438500_CIT0058","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1136\/gutjnl-2021-326462","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: a nationwide Danish cohort study","volume":"71","author":"Ward","year":"2022","journal-title":"Gut."},{"key":"2025071703213438500_CIT0059","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","article-title":"Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study","volume":"62","author":"Rungoe","year":"2013","journal-title":"Gut."},{"key":"2025071703213438500_CIT0060","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/j.cgh.2016.02.016","article-title":"Effectiveness and safety of vedolizumab induction therapy for patients with inflammatory bowel disease","volume":"14","author":"Amiot","year":"2016","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0061","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/apt.14167","article-title":"One-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: a prospective multicentre cohort study","volume":"46","author":"Amiot","year":"2017","journal-title":"Aliment Pharmacol Ther."},{"key":"2025071703213438500_CIT0062","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1111\/apt.16544","article-title":"Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study","volume":"54","author":"Fumery","year":"2021","journal-title":"Aliment Pharmacol Ther."},{"key":"2025071703213438500_CIT0063","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1093\/ecco-jcc\/jjaa177","article-title":"Effectiveness and safety of ustekinumab intensification at 90\u00a0mg every 4 weeks in Crohn\u2019s disease: a multicentre study","volume":"15","author":"Fumery","year":"2021","journal-title":"J Crohns Colitis."},{"key":"2025071703213438500_CIT0064","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ijcard.2023.02.042","article-title":"Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: a systematic review with meta-analysis","volume":"378","author":"D\u2019Ascenzo","year":"2023","journal-title":"Int J Cardiol."},{"key":"2025071703213438500_CIT0065","doi-asserted-by":"crossref","first-page":"e002483","DOI":"10.1136\/openhrt-2023-002483","article-title":"Inflammatory bowel disease patients have an increased risk of acute coronary syndrome: a systematic review and meta-analysis","volume":"10","author":"Zaka","year":"2023","journal-title":"Open Heart"},{"key":"2025071703213438500_CIT0066","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1177\/2047487318792952","article-title":"Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis","volume":"25","author":"Sun","year":"2018","journal-title":"Eur J Prev Cardiol."},{"key":"2025071703213438500_CIT0067","doi-asserted-by":"crossref","first-page":"e005892","DOI":"10.1161\/JAHA.117.005892","article-title":"Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies","volume":"6","author":"Feng","year":"2017","journal-title":"J Am Heart Assoc."},{"key":"2025071703213438500_CIT0068","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1053\/j.gastro.2021.07.042","article-title":"Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management","volume":"161","author":"Rogler","year":"2021","journal-title":"Gastroenterology."},{"key":"2025071703213438500_CIT0069","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4330\/wjc.v15.i11.553","article-title":"Cardiovascular implications of inflammatory bowel disease: an updated review","volume":"15","author":"Bhardwaj","year":"2023","journal-title":"World J Cardiol"},{"key":"2025071703213438500_CIT0070","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.tcm.2019.10.001","article-title":"Inflammatory bowel disease and the risk for cardiovascular disease: does all inflammation lead to heart disease","volume":"30","author":"Bigeh","year":"2020","journal-title":"Trends Cardiovasc Med."},{"key":"2025071703213438500_CIT0071","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1016\/j.jacc.2020.10.027","article-title":"Inflammatory bowel disease and atherosclerotic cardiovascular disease","volume":"76","author":"Cainzos-Achirica","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"2025071703213438500_CIT0072","doi-asserted-by":"crossref","first-page":"oeab029","DOI":"10.1093\/ehjopen\/oeab029","article-title":"Inflammatory bowel disease and cardiovascular diseases: a concise review","volume":"2","author":"Wu","year":"2022","journal-title":"Eur Heart J Open."},{"key":"2025071703213438500_CIT0073","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-12-47","article-title":"Is atherosclerosis an autoimmune disease","volume":"12","author":"Matsuura","year":"2014","journal-title":"BMC Med."},{"key":"2025071703213438500_CIT0074","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/j.gastro.2011.02.016","article-title":"Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases","volume":"140","author":"Strober","year":"2011","journal-title":"Gastroenterology."},{"key":"2025071703213438500_CIT0075","doi-asserted-by":"crossref","first-page":"102956","DOI":"10.1016\/j.ebiom.2020.102956","article-title":"Effects of tumour necrosis factor on cardiovascular disease and cancer: a two-sample Mendelian randomization study","volume":"59","author":"Yuan","year":"2020","journal-title":"EBioMedicine."},{"key":"2025071703213438500_CIT0076","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/1475-2840-12-126","article-title":"Interleukin-6 and activin A are independently associated with cardiovascular events and mortality in type 2 diabetes: the prospective Asker and B\u00e6rum Cardiovascular Diabetes (ABCD) cohort study","volume":"12","author":"Ofstad","year":"2013","journal-title":"Cardiovasc Diabetol."},{"key":"2025071703213438500_CIT0077","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1016\/j.jacc.2020.08.026","article-title":"Interleukin-1\u03b2 and risk of premature death in patients with myocardial infarction","volume":"76","author":"Silvain","year":"2020","journal-title":"J Am Coll Cardiol."},{"key":"2025071703213438500_CIT0078","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.humimm.2011.04.005","article-title":"Association between nod2\/card15 polymorphisms and coronary artery disease: a case\u2013control study","volume":"72","author":"Galluzzo","year":"2011","journal-title":"Hum Immunol."},{"key":"2025071703213438500_CIT0079","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/apt.15562","article-title":"Crohn\u2019s disease and ulcerative colitis are associated with different lipid profile disorders: a nationwide population-based study","volume":"51","author":"Soh","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"key":"2025071703213438500_CIT0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15420\/ecr.2019.06","article-title":"New perspectives on atherogenic dyslipidaemia and cardiovascular disease","volume":"15","author":"Lorenzatti","year":"2020","journal-title":"Eur Cardiol Rev."},{"key":"2025071703213438500_CIT0081","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1007\/s10620-024-08348-2","article-title":"Risk of adverse cardiovascular outcomes in postmenopausal women with inflammatory bowel disease","volume":"69","author":"Greywoode","year":"2024","journal-title":"Dig Dis Sci."},{"key":"2025071703213438500_CIT0082","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1038\/ajg.2009.81","article-title":"Risk of arterial thrombotic events in inflammatory bowel disease","volume":"104","author":"Ha","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"2025071703213438500_CIT0083","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0084","first-page":"71","article-title":"Effects of tofacitinib and other DMARDs on lipid profiles in rheumatoid arthritis: implications for the rheumatologist","volume-title":"Semin Arthritis Rheum","author":"Charles-Schoeman","year":"2016"},{"key":"2025071703213438500_CIT0085","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacl.2017.06.012","article-title":"Effect of tofacitinib on lipid levels and lipid-related parameters in patients with moderate to severe psoriasis","volume":"11","author":"Wolk","year":"2017","journal-title":"J Clin Lipidol."},{"key":"2025071703213438500_CIT0086","author":"Administration WDoHTG","year":"2023"},{"key":"2025071703213438500_CIT0087","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1080\/17474124.2023.2194631","article-title":"Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials","volume":"17","author":"Shehab","year":"2023","journal-title":"Expert Rev Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0088","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/apt.17509","article-title":"Risk of cardiovascular events in patients with inflammatory bowel disease receiving small molecule drugs","volume":"57","author":"Olivera","year":"2023","journal-title":"Aliment Pharmacol Ther."},{"key":"2025071703213438500_CIT0089","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","article-title":"Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis","volume":"22","author":"Mattay","year":"2024","journal-title":"Clin Gastroenterol Hepatol."},{"key":"2025071703213438500_CIT0090","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG clinical guideline: management of Crohn\u2019s disease in adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol."}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjaf078\/63103210\/jjaf078.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf078\/63103210\/jjaf078.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/19\/5\/jjaf078\/63103210\/jjaf078.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T07:21:47Z","timestamp":1752736907000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjaf078\/8126551"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":90,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,8]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaf078","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,5]]},"published":{"date-parts":[[2025,5]]},"article-number":"jjaf078"}}